For Immediate Release
Contact: Lisa Finger, 919-933-2021, lfinger@biosignia.com

BioSignia, Inc. Announces Research Agreement with Aurigen Reinsurance Company
Sponsored Research Project to Explore Cognitive Function as Indicator of Mortality Risk

Research Triangle Park, North Carolina – October 10, 2011 — BioSignia, a predictive modeling company providing innovative solutions for the healthcare and life insurance industries, today announced the signing of a sponsored research agreement with Aurigen Reinsurance Company (“Aurigen”), a life and health reinsurance company in Canada. BioSignia will conduct research under a three-month contract with Aurigen that will investigate correlations between cognitive function and mortality.

BioSignia’s Chief Scientific Officer, Dr. Guizhou Hu, will serve as lead investigator on the project. “Cognitive function has been found to be inversely associated with subsequent mortality in elderly adults in several clinical studies,” said Dr. Hu. “In our research efforts with Aurigen we hope to further expand the understanding of specific cognitive function measures as an indicator of mortality risk for both elderly and middle-aged populations.”

“Aurigen is excited to collaborate with Dr. Hu and the staff at BioSignia to further our knowledge in mortality risk assessment,” said Bob Brown, Chief Pricing Officer with Aurigen.

For more information on BioSignia’s research or market applications, please call 888.324.6627 or email info@biosignia.com.

# # #

About BioSignia
Headquartered in Research Triangle Park, N.C., BioSignia is a leading technology company focused on bringing innovative predictive modeling solutions to the life insurance and preventive healthcare markets. BioSignia’s patented technology, Synthesis Analysis™, provides the underpinnings of BioSignia’s life insurance application, Mortality Assessment Technology™ (MAT). This modeling capability represents a quantum leap forward in both morbidity and mortality risk assessment. In 2004, BioSignia received the award for Best Enabling Tool for Disease Management from DMAA: The Care Continuum Alliance. Since then, BioSignia’s talented R&D team has continued to advance synthesis modeling, continuously updating it to reflect the ever expanding need for better risk assessment as well as effective chronic disease prevention, management and treatment. For more information about BioSignia, visit: www.biosignia.com.

About Aurigen Reinsurance Company

Aurigen’s core business is the reinsurance of individual life insurance policies. It has 38 employees and is currently licensed to transact life reinsurance in Canada and Bermuda. Aurigen’s operating life reinsurance companies each have financial strength ratings of A- (Excellent) from A.M. Best, life reinsurance in force in excess of CAD $20 billion and consolidated assets in excess of CAD $250 million.

BioSignia, Inc. • 401 Harrison Oaks Blvd., Suite 120 • Cary, NC 27513 • (919) 933-2021 • (888) 324-6627